AVE 8112

Drug Profile

AVE 8112

Alternative Names: AVE 8112A; AVE8112

Latest Information Update: 05 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis; The Michael J. Fox Foundation for Parkinson's Research
  • Class Antidementias
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 02 Oct 2015 Discontinued - Phase-I for Parkinson's disease (Adjunctive treatment) in USA (PO)
  • 01 Jan 2013 Phase-I clinical trials in Parkinson's disease (adjunctive treatment) in USA (PO)
  • 19 Apr 2012 Sanofi enters into a collaboration with the Michael J. Fox Foundation for a clinical trial in Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top